View More Recent Stories

Feb 18, 2025 04:43AM Organon (OGN) call put ratio 47 calls to 1 put with focus on March 17.50 calls
Feb 14, 2025 03:52PM Organon (OGN) March 17.50 calls active as share price down 5.6%
Feb 14, 2025 11:58AM Organon & Co. (OGN) PT Lowered to $19 at Goldman Sachs
Feb 13, 2025 07:40AM Organon (OGN) Misses Q4 EPS by 1c ; Offers Guidance
Jan 14, 2025 02:05PM TD Cowen Assumes Organon & Co. (OGN) at Hold
Jan 7, 2025 11:00AM TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
Jan 2, 2025 12:39PM TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
Dec 16, 2024 07:30AM Organon (OGN) Announces FDA Approval of VTAMA cream
Nov 5, 2024 07:29AM Organon (OGN) Issues Update on FDA Review of VTAMA Cream
Oct 31, 2024 07:35AM Organon (OGN) Misses Q3 EPS by 3c, provides guidance
Oct 30, 2024 06:05AM Organon (OGN) Announces FDA Acceptance of BLA for HLX14
Oct 28, 2024 09:25AM Organon (OGN) Completes Acquisition of Dermavant
Oct 7, 2024 09:16AM TD Cowen Reiterates Hold Rating on Organon & Co. (OGN)
Sep 30, 2024 06:06AM Organon (OGN) Reports Primary Endpoint Met in Phase 3 Comparative Clinical Study of HLX11
Sep 23, 2024 04:27PM Organon (OGN) enters merger agreement with Dermavant Sciences
Sep 18, 2024 07:30AM Organon (OGN) to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA Cream, 1%
Sep 6, 2024 03:35AM JPMorgan Downgrades Organon & Co. (OGN) to Underweight
Aug 25, 2024 02:00AM 3 ways to gain stock market exposure to the fertility theme
Aug 20, 2024 07:31AM Organon (OGN) and Lilly (LLY) Expand Migraine Commercialization Agreement to 11 Additional Markets
Aug 6, 2024 07:37AM Organon (OGN) Tops Q2 EPS by 4c ; Offers Guidance
Jul 24, 2024 11:00PM These stocks offer you exposure to rising demand for fertility treatment – Barclays
View More Recent Stories